Eculizumab is a monoclonal antibody against complement C5 that is manufactured by Alexion Pharmaceuticals. It first received US Food and Drug Administration (FDA) approval in 2007 for treatment of paroxysmal nocturnal hemoglobinuria, a rare disease with incidence of 1 to 10 per million and, when it debuted, was the most costly drug in the world, priced at $400 000 per year for indefinite use.1,2
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Kim MS, Prasad V. The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab. JAMA Intern Med. 2020;180(2):315–317. doi:10.1001/jamainternmed.2019.4694
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: